Efficacy, Health-Related Outcomes, and Safety of Ixekizumamb for up to Five Years of Open-Label Treatment in a Phase 2 Study in Chronic Plaque Psoriasis. J of Skin [Internet]. 2017 Oct. 27 [cited 2025 Apr. 19];1(3.1):s12. Available from: https://skin.dermsquared.com/skin/article/view/174